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Qi siteAscochlorin is an isoprenoid antibiotic that is produced by the phytopathogenic fungus Ascochyta viciae.
Similar to ascofuranone, which speciﬁcally inhibits trypanosome alternative oxidase by acting at the
ubiquinol binding domain, ascochlorin is also structurally related to ubiquinol. When added to the
mitochondrial preparations isolated from rat liver, or the yeast Pichia (Hansenula) anomala, ascochlorin
inhibited the electron transport via CoQ in a fashion comparable to antimycin A and stigmatellin, indicating
that this antibiotic acted on the cytochrome bc1 complex. In contrast to ascochlorin, ascofuranone had much
less inhibition on the same activities. On the one hand, like the Qi site inhibitors antimycin A and funiculosin,
ascochlorin induced in H. anomala the expression of nuclear-encoded alternative oxidase gene much more
strongly than the Qo site inhibitors tested. On the other hand, it suppressed the reduction of cytochrome b
and the generation of superoxide anion in the presence of antimycin A3 in a fashion similar to the Qo site
inhibitor myxothiazol. These results suggested that ascochlorin might act at both the Qi and the Qo sites of
the fungal cytochrome bc1 complex. Indeed, the altered electron paramagnetic resonance (EPR) lineshape of
the Rieske iron–sulfur protein, and the light-induced, time-resolved cytochrome b and c reduction kinetics
of Rhodobacter capsulatus cytochrome bc1 complex in the presence of ascochlorin demonstrated that this
inhibitor can bind to both the Qo and Qi sites of the bacterial enzyme. Additional experiments using puriﬁed
bovine cytochrome bc1 complex showed that ascochlorin inhibits reduction of cytochrome b by ubiquinone
through both Qi and Qo sites. Moreover, crystal structure of chicken cytochrome bc1 complex treated with
excess ascochlorin revealed clear electron densities that could be attributed to ascochlorin bound at both the
Qi and Qo sites. Overall ﬁndings clearly show that ascochlorin is an unusual cytochrome bc1 inhibitor that
acts at both of the active sites of this enzyme.roxyquinoline-N-oxide; nQNO,
cyl-1,4-benzoquinone; DBH2,
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Ascofuranone and ascochlorin are antibiotics produced by the
phytopathogenic fungus Ascochyta viciae, and both have closely
related prenylphenol structures (Fig. 1A and B) [1]. Ascofuranone
speciﬁcally inhibits trypanosome alternative oxidase, and is consid-
ered to be a promising candidate as a chemotherapeutic agent against
African trypanosomiasis [2,3]. Kinetic analyses with puriﬁed recom-
binant trypanosome alternative oxidase demonstrated that the site ofinhibition of ascofuranone is the ubiquinol binding domain of this
enzyme [4].
Ascochlorin was found to inhibit the respiratory chain [5,6], and its
chemical structure was determined by X-ray analyses [7,8]. Since
then, many structurally related compounds have been isolated from a
variety of fungi, including Fusarium sp. LL-Z1272 [9], Colletotrichum
sp. [10], Cylindrocladium sp. [11], Cylindrocladium ilicicola MFC-870
[12,13], Acremonium luzulae [14], and Verticillium sp. [15]. Ascochlorin
glycoside was also isolated from the insect pathogenic fungus Verti-
cillium hemipterigenum [16]. These compounds have been reported to
show antiviral and antitumor activities [6,12,16]. In addition, the
independently isolated compounds LL-Z1272γ and ilicicolin D that are
responsible for the antifungal activity of the coprophilous fungus Ni-
grosabulum globosum were found to be identical to ascochlorin
[13,17]. Moreover, some members of the ascochlorin family from
Cylindrocarpon lucidum also inhibit farnesyl-protein transferase
enzyme [18]. For example, the 4-O-carboxymethylated derivative of
ascochlorin (AS-6) has considerable physiological effects on the
Fig. 1. Chemical structures. (A) Ascofuranone. (B) Ascochlorin. (C) LL-Z1272ɛ.
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to enhance the Ca2+ binding on the plasma membranes of adipocytes
[20], and 4-O-methyl ascochlorin induces apoptosis in Jurkat cells
[21]. Ascochlorin can also suppress activation of the nuclear
transcription factor activator protein-1 in several cancer cell lines
[22,23], and activate p53 probably as a result of inhibition of
mitochondrial respiration [24]. More recently, it has been shown
that ascochlorin strongly inhibited ubiquinol oxidases (Escherichia coli
cytochrome bo and Trypanosoma vivax alternative oxidase), which is
not surprising due to its close structural resemblance to ubiquinol
[25].
According to the protonmotive Q cycle, the cytochrome bc1
complex has two quinone binding sites: the Qo site where ubiquinol
is oxidized and the Qi site where ubiquinone is reduced [26]. A
number of inhibitors speciﬁc for the Qo and Qi sites of the cytochrome
bc1 complex have been studied intensively to understand the Q cycle
mechanism of this enzyme [27]. Among them, antimycin A, NQNO⁎,
funiculosin, ilicicolin H, and dichlorophenyl dimethyl urea (diuron)
are well-known Qi site inhibitors [27,28], whereas the Qo site
inhibitors include stigmatellin, various hydroxyquinones and myx-
othiazol. The latter molecules block the “bifurcated electron transfer
reaction” during which one of the two electrons resulting from
oxidation of ubiquinol at the Qo site reduces the Rieske iron–sulfur
protein (and subsequently cytochrome c1), whereas the other
electron is recycled back to the quinol pool via the cytochrome b
hemes. Currently, a signiﬁcant amount of structural information is
available regarding the binding of these inhibitors that exhibit speciﬁc
modes of actions [29-31]. Generally, the cytochrome bc1 inhibitors
seem to be speciﬁc for one of the two active Q centers. With the
exception of NQNO [32], none of the inhibitors has so far been
reported to bind both at Qo and Qi sites simultaneously.
Here we show that ascochlorin is a new kind of speciﬁc inhibitor of
the cytochrome bc1 complex as it affects both of the Qo and Qi sites.
First, the effect of ascochlorin was examined on the respiratory chains
of the ascomycetous yeast Hansenula (Pichia) anomala that has a
cyanide-resistant respiratory pathway catalyzed by an alternative
oxidase [33-35]. Considering the previous data that antimycin Ahighly induced the cyanide-resistant respiratory activity ofH. anomala
(i.e., the expression of the nuclear-encoded alternative oxidase gene),
whereas myxothiazol or stigmatellin showed little effect on the
expression of this activity [36,37], we thought that ascochlorin might
inhibit the fungal cytochrome bc1 complex through both the Qi and Qo
sites of the enzyme. Together with additional spectroscopic analyses
using the vertebrate and bacterial enzymes, and the X-ray structure of
the avian cytochrome bc1 complex bound with ascochlorin, we show
that this inhibitor binds to both of the Qo and Qi sites of the enzyme.
2. Materials and methods
2.1. Materials
Ascochlorin and its derivatives and ascofuranone were all isolated
and prepared as reported [1,19]. Antimycin A3, myxothiazol, dithio-
nite, bovine erythrocyte superoxide dismutase, horse heart cyto-
chrome c, and 2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone
(DB) were purchased from Sigma Chemical Co.; stigmatellin was
from Fluka Biochemica; and SF6847 was from Wako Pure Chemical
Industries Ltd. Funiculosin and atovaquone were generous gifts from
Sandoz and GlaxoSmithKline, respectively. Nonylhydroxydioxoben-
zothiazole (NHDBT) was provided by Dr. Bernard L. Trumpower
(Dartmouth Medical School), and LL-Z1272ɛ was kindly provided by
Dr. Akira Takatsuki (Hosei University). Azoxystrobin was a gift from
Steve Heaney (Zeneca Agrochemicals). Oxidized DB was reduced to
DBH2 by the procedure of Trumpower and Edwards [38].
2.2 Preparation of mitochondria, bacterial chromatophores, and
vertebrate cytochrome bc1 complex
The cyanide-sensitive mitochondrial fraction was prepared from
freshly harvested cells of H. anomala, as described in our previous
report [34]. Succinate-dependent oxygen uptake activity of the yeast
preparation was about 0.178 μmol O2/min/mg protein. The rat liver
mitochondrial fraction was prepared from adult male Wistar rats
according to the method of Johnson and Lardy [39]. Succinate-
dependent oxygen uptake activity of the liver preparation was about
0.155 μmol O2/min/mg protein. The preparations retained clear
respiratory control and were responsive to ADP addition. Chromato-
phoremembranes from Rhodobacter capsulatus cells were prepared as
described [40]. The cytochrome bc1 complexes of chicken and beef
were puriﬁed as described previously [29,30].
2.3 Induction of cyanide-resistant respiration
Freshly harvested H. anomala cells resuspended in 1 ml of 2 mM
potassium phosphate buffer (pH 6.5, A600=25, 52.4 mg wet cells/ml)
were shaken aerobically at 30 °C for 2 h with or without the addition
of appropriate inhibitors. Samples (50 μl) were withdrawn and
assayed for cyanide-resistant respiratory activity as previously
described [33].
2.4. Analytical methods
Oxygen uptake activity was determined polarographically with an
oxygen electrode (model 5331, Yellow Springs Instrument Co., Inc.
Ohio) in a 1-ml glass chamber maintained at 30 °C. Cyanide-sensitive
O2 uptake was measured in the presence of 50 nM SF6847.
Mitochondrial fractions resuspended in 0.3 M sucrose, 10 mM
potassium phosphate, 10 mM Tris–HCl, 10 mM KCl, 5 mM MgCl2,
and 0.2 mM EDTA (pH 7.4) were pre-incubated with the inhibitors,
and the reaction was initiated by the addition of respiratory
substrates, as indicated in the tables. Cyanide-sensitive and cyanide-
resistant O2 uptake activities were determined according to our
previous report [33,34], and the molar concentrations of the inhibitor
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The relative extent of cytochrome b reduction was determined at
30 °C using a stirred cuvette in a Hitachi 557 spectrophotometer,
operating in the dual-wavelength mode using the 560–575 wave-
length pair. The H. anomala mitochondrial fraction (5.46 mg) was
suspended in 2 ml of 0.3 M sucrose, 10 mM potassium phosphate,
10mM Tris–HCl, 10 mMKCl, 5 mMMgCl2, and 0.2 mM EDTA (pH 7.4).
Estimation of O2−• generation was carried out using 2-methyl-6-(p-
methoxyphenyl)-3,7-dihydroimidazo[1,2-α]pyrazin-3-one (MCLA)
according to our previously described method [34]. The increase in
chemiluminescence intensity (the peak height reﬂecting O2−• gener-
ation rate) sensitive to 0.5 μM superoxide dismutase was determined.
For EPR spectroscopy, 10–30 μM (ﬁnal concentration) of inhibitor
dissolved in dimethylsulfoxide were added to chromatophore
membrane samples (approximately 30 mg/ml total membrane
proteins concentration). Chemical reduction of the samples was
achieved by addition of sodium ascorbate to 5mM ﬁnal concentration,
and samples were stored in liquid nitrogen until the spectra were
recorded. EPR spectroscopywas carried out at sample temperatures of
20 K, 9.44 GHz microwave frequency attenuated to 2 mW of power
with modulation amplitudes of 12 Gauss, using a Bruker ESP 300E
spectrometer (Bruker Biosciences, Inc.), ﬁtted with an Oxford
Instrument ESR-9 helium cryostat (Oxford Instrumentation, Inc.), as
reported in [41].
Time-resolved, light-activated kinetic spectroscopy was per-
formed on a dual-wavelength kinetic spectrophotometer with
chromatophore membranes resuspended in 50 mM MOPS buffer
(pH 7.0) containing 100 mM KCl for the Qo site-mediated forward
reactions as described by Lee et al. [42], or in 50 mM glycine–NaOH
buffer (pH 9.5) containing 100mMKCl and 10 μMmyxothiazol for the
Qi site-mediated reverse reactions as described by Saribas et al. [43]
and Roberson and Dutton [44] in the presence of the following redox
mediators (with their respective Em,7): 100 μM ferricyanide (FeCN,
430 mV), 8 μM 2,3,5,6-tetramethyl-p-phenylenediamine (DAD,
260 mV), 6 μM 1,2-naphthoquinone (NQ, 145 mV), 1 μM phenazine
methosulfate (PMS, 80 mV), 1 μM phenazine ethosulfate (PES,
50 mV), 6 μM 2-hydroxy-1,4-naphthoquinone (HNQ,-145 mV), 6 μM
benzyl viologen (BV,-359 mV), and a membrane potential uncoupler
(2.5 μM valinomycin), as described [45].
The amount of chromatophore membranes used in each assay was
normalized to the reaction center content, as determined by
measuring the ﬂash-induced optical absorbance difference between
605 nm and 540 nm at an Eh of 380 mV, and using an extinction
coefﬁcient of 29.8 mM−1 cm−1. Transient cytochrome c re-reduction
and cytochrome b reduction kinetics were monitored at an ambient
potential of 100 mV for the forward reaction, and at 125 mV for the
reverse reaction, respectively. The cytochrome c and cytochrome b
kinetics were initiated by a short saturating ﬂash (∼8 μs) from a xenon
lamp and followed at 550–540 nm and at 560–570 nm, respectively.
Antimycin, myxothiazol and stigmatellin were used as indicated at 20,Table 1
Effects of ascochlorin and related compounds on the O2 uptake activities of H. anomala mit
Inhibitors IC50 (μM)
15 mM malate + 15 mM pyruvate 15 mM su
Ascofuranone 230 14.5
Ascochlorin 0.045 0.036
4-O-Methyl ascochlorin 5.9 4.8
4-O-Carboxymethyl ascochlorin 58.5 43.5
4-O-Nicotinoyl ascochlorin 0.37 0.74
Antimycin A3 0.035 0.020
Funiculosin 0.250 0.145
Stigmatellin 0.042 0.028
Myxothiazol 0.085 0.073
H. anomala mitochondria fraction (0.175 mg protein) was added to the assay mixture. In t
dehydrogenase.10, and 10 μM, respectively. Ascochlorin was added at a ﬁnal
concentration of 1 or 10 μM, as indicated.
Inhibition of the cytochrome b reduction through both Q sites
(“double-kill” experiment) by ascochlorinwasmeasuredusingpuriﬁed
bovine cytochrome bc1 complex. The enzyme was diluted to 3 or 6 μM
in 20 mM potassium MOPS buffer (pH 7.2) containing 100 mM NaCl,
0.5 mM EDTA, and 0.1 g/l dodecyl maltoside. Spectra were scanned in
the range 520–580 nm before and at ∼18-s intervals after addition of
the ubiquinol analog DBH2 (∼2 μM) using an Aminco DW2 spectro-
photometer operating in the double beam mode. The fully oxidized
spectrum was subtracted from all. Difference spectra (Fig. 4) were
decomposed into difference spectra of the individual cytochromes to
determine the reduction level of cytochromes c1, bH, and bL by the
generalized inverse matrix method of [46] using the “scanedit”
program available at sourceforge.net (http://scanedit.sourceforge.net/
). The standard difference spectra of the pure cytochromes for use in
this method were determined from a global ﬁt to whole-spectral
titrations of puriﬁed bovine bc1 complex, as described for the potato bc1
complex [47] and are included in supplemental materials for this paper.
Where antimycin and azoxystrobin were included (Fig. 4A and B), the
red-shift spectrum of the appropriate inhibitor was also included in the
standard spectra used for analysis.
For structural studies, the chicken cytochrome bc1 complex was
crystallized as described by Zhang et al. [29], or by using a slight
modiﬁcation to be reported (manuscript in preparation). After
crystallization, ascochlorin was added to the mother liquor at a
stoichiometry of three molecules of inhibitor per monomer of the
cytochrome bc1 complex. Inhibitor-soaked crystals were cryo-
protected by dipping in a solution of 25% glycerol, 12% polyethylene
glycol 4000, 10 mM potassium MES (pH 6.7), 3 mM NaN3, and 0.1 g/
l dodecyl maltoside before freezing in liquid nitrogen for cryogenic
data collection. Diffraction data were collected at beamline 5.0.2 at the
ALS. The best diffraction datasets were solved by rigid-body
reﬁnement of the available chicken cytochrome bc1 complex structure
(PDB accession code: 3H1J) against the new data followed by cycles of
automated reﬁnement (positional and individual atomic B-factor
reﬁnement) and manual rebuilding. Strong non-crystallographic
symmetry restraints were imposed during positional reﬁnement,
but not during B-factor reﬁnement. The best dataset was reﬁned to R
and Rfree of 0.267 and 0.295, respectively, for 125,000 unique
reﬂections at resolution between 30 and 3.21 Å. Statistics from data
processing and structure reﬁnement are presented in Table 6, and the
structure has been deposited to the PDB with accession code 3H1L.
3. Results
Table 1 illustrates the inhibitory effects of ascochlorin on the O2
uptake activities of H. anomala mitochondria using ﬁve kinds of
respiratory substrate. Clearly, ascochlorin inhibited strongly all O2
uptake activities in amanner comparable to the inhibition by antimycinochondria.
ccinate 1 mM NADH 1 mM duroquinol 20 mM glycerol-3-phosphate
68.5 52.0 36.5
0.035 0.034 0.043
9.5 4.2 5.8
44.0 79.5 22.0
0.40 0.60 0.54
0.021 0.027 0.026
0.230 0.065 0.195
0.029 0.030 0.030
0.069 0.047 0.067
his preparation, NADH oxidation is catalyzed by rotenone-insensitive external NADH-
Table 2
Effects of ascochlorin and related compounds on the succinate-dependent O2 uptake
activity in rat liver mitochondria.
Inhibitors IC50 (μM)
Ascofuranone 16.0
Ascochlorin (LL-Z1272γ) 0.013
4-O-Methyl ascochlorin 0.120
4-O-Carboxymethyl ascochlorin 4.1
4-O-Nicotinoyl ascochlorin 0.080
LL-Z1272ɛ 3.84
Antimycin A3 0.0115
Funiculosin 0.280
Stigmatellin 0.014
Myxothiazol 0.0165
The rat liver mitochondrial fraction (0.196 mg protein) and 15 mM succinate were
added to the assay mixture.
Table 4
Effects of respiratory inhibitors on the reduction of cytochrome b in the H. anomala
mitochondria.
Additions ΔA560–575×102
15 mM Succinate 0.83
+10 μM Antimycin A3 1.28
+10 μM Ascochlorin 0.85
+Dithionite 1.72
15 mM Succinate 0.92
+10 μM Ascochlorin 0.92
+10 μM Antimycin A3 0.94
+Dithionite 1.76
15 mM Succinate 0.86
+10 μM Antimycin A3 1.27
+10 μM Myxothiazol 1.03
+Dithionite 1.76
15 mM Succinate 0.94
+10 μM Myxothiazol 1.16
+10 μM Antimycin A3 1.08
+Dithionite 1.71
The H. anomala mitochondrial fraction (5.46 mg) suspended in 2 ml of 0.3 M sucrose,
10 mM potassium phosphate, 10 mM Tris, 10 mM KCl, 5 mM MgCl2, and 0.2 mM EDTA
(pH 7.4) was pre-incubated at 30 °C, and then 30 μl of 1 M sodium succinate was added
to the mixture. Absorbance changes were monitored at 560 minus 575 nm as described
in Materials and methods. The inhibitors and dithionite were added sequentially as
indicated.
Table 5
Superoxide anion generation in the H. anomala mitochondria in the presence of
respiratory inhibitors.
Additions Chemiluminescence intensity (105 counts/min)
15 mM Succinate 2.0
+10 μM Antimycin A3 9.1
+10 μM Ascochlorin 4.6
15 mM Succinate 1.8
+10 μM Ascochlorin 2.6
+10 μM Antimycin A3 3.6
15 mM Succinate 1.9
+10 μM Antimycin A3 8.8
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the same activities, in spite of its close structural relatedness to
ascochlorin. Similarly, the three different derivatives of ascochlorin,
which have chemical modiﬁcations at the 4-OH group of the benzene
ring, also exhibited signiﬁcantly weaker inhibitor activities.
Next, the effects of ascochlorin on the rat liver mitochondria were
examined (Table 2). Comparable to the data shown in Table 1,
ascochlorin had potent inhibitory effects, which were similar to those
seen with antimycin A3, stigmatellin, and myxothiazol, whereas
ascofuranone had much less effect. Similarly, the three 4-OH deriva-
tives of ascochlorin also exhibitedmuch lower inhibitor activities. Note
that the antibiotic LL-Z1272ɛ differs from ascochlorin by lacking a Cl
atom at C5 of the benzene ring with 4′,5′-dihydrogenated isoprenoid
side chain (Fig. 1C). Inhibition of the tested activity by this antibiotic
was about 1/300 of that seen using ascochlorin.
Table 3 documents the induction of cyanide-resistant respiratory
activity in H. anomala, where nuclear-encoded alternative oxidase
gene expression is drastically stimulated in the presence of antimycin
A [36]. Interestingly, like antimycin A3, ascochlorin also induced
cyanide-resistant respiratory activity. Funiculosin, which had less
inhibitory effect on the O2 uptake activities (Table 1), also induced the
alternative pathway but to a lesser extent. In contrast, all of the Qo site
inhibitors tested induced cyanide-resistant respiration only slightly.
Thus, like the other Qi site inhibitors, ascochlorin also seemed to
trigger mitochondrial signaling toward the nucleus for increased
expression of the alternative oxidase gene in H. anomala.
Table 4 documents the suppressive effects of ascochlorin on the
cytochrome b reduction seen in the presence of succinate and
antimycin A3. The antimycin A3-dependent reduction of cytochrome
b was strongly inhibited following addition of ascochlorin. Consider-
ing that myxothiazol also have similar inhibitory effects, this ﬁnding
suggested that ascochlorin might bind at the Qo site to block the
bifurcated electron ﬂow to the cytochrome b like many Qo site
inhibitors. Furthermore, Table 5 shows similar suppressive effects of
ascochlorin on antimycin A3-dependent superoxide anion generation
by theH. anomalamitochondria. As we reported earlier [34,37], in thisTable 3
Induction of cyanide-resistant respiration in H. anomala in the presence of respiratory
inhibitors.
Additions CN-resistant O2 uptake activity (nmol O2/min/mg wet cells)
None 0.181
10 μMAntimycinA3 7.77
10 μM Ascochlorin 7.42
10 μM Funiculosin 3.12
10 μM Stigmatellin 0.433
10 μM Myxothiazol 0.375
10 μM Atovaquone 0.202
10 μM NHDBT 0.225species, the rate of superoxide generation is signiﬁcantly increased in
the presence of antimycin A and respiratory substrates. This effect was
readily suppressed by ascochlorin in a fashion similar to that observed
with myxothiazol or stigmatellin. Recently, antimycin A plus
substrate-dependent increase of superoxide production was reported
to be suppressed by addition of stigmatellin to bovine heart
submitochondrial particles [48]. Thus, our data shown in Tables 4
and 5 suggest that the mode of action of ascochlorin on the
cytochrome bc1 complex is similar to the Qo site inhibitors.
3.1. Ascochlorin affects the EPR lineshape of the reduced Fe2S2 cluster
Additional evidence that ascochlorin binds at the Qo site of the
cytochrome bc1 complex was obtained by comparing the EPR spectra
of the reduced Rieske iron–sulfur protein in chromatophore+10 μM Myxothiazol 5.4
15 mM Succinate 2.1
+10 μM Myxothiazol 3.3
+10 μM Antimycin A3 5.6
15 mM Succinate 1.6
+10 μM Antimycin A3 8.9
+10 μM Stigmatellin 4.7
15 mM Succinate 1.7
+10 μM Stigmatellin 2.7
+10 μM Antimycin A3 4.8
The H. anomala mitochondrial fraction (0.18 mg) suspended in 1 ml of 0.3 M sucrose,
10 mM potassium phosphate, 10 mM Tris, 10 mM KCl, 0.05 mMMgCl2, and 4 μMMCLA
(pH 7.0) was pre-incubated at 30 °C in a chemiluminescence reader (Aloka, BLR-102),
and then 15 μl of 1 M sodium succinate was added to the mixture. The increase in
chemiluminescence intensity was determined as described in Materials and methods.
The inhibitors were added sequentially as indicated.
Fig. 2. EPR spectra of the iron–sulfur cluster of R. capsulatus bc1 complex in the presence
of ascochlorin and other ligands.
364 E.A. Berry et al. / Biochimica et Biophysica Acta 1797 (2010) 360–370membranes of the photosynthetic bacterium R. capsulatus recorded in
the presence and absence of ascochlorin and other Qo site inhibitors
(Fig 2). Stigmatellin sharpens and shifts towards higher magneticFig. 3. Light-induced, time-resolved single turnover cytochrome c re-reduction and cytochr
containing 0.28 μM reaction center were resuspended in 50mMMOPS buffer (pH 7.0)/100m
with appropriate mediators (see Materials and methods). For the forward reaction, the redo
7.0 (A) or at 125 mV where the Qpool is fully oxidized at pH 9.5 (B) for the reverse reaction.
cytochrome c re-reduction and cytochrome b reduction following a short (8 μs) ﬂash of ligﬁelds the Rieske ISP gx EPR transition at g=1.768. On the other hand,
myxothiazol, which displaces ubiquinone from the Qo site, yields a
broader signal shifted towards lower magnetic ﬁelds. Clearly,
ascochlorin also changes the gx transition of the Rieske ISP, suggesting
that it indeed binds to the Qo site of the cytochrome bc1 complex. Note
that under these experimental conditions the inhibitors that interact
with the Qi site exhibit no effect on the EPR gx transitions.
3.2. Dual-site action in bacterial and vertebrate bc1 complex
In order to gain insight into the mode of action of ascochlorin at
both the Qo and Qi sites of the cytochrome bc1 complex, wemonitored
the light-induced single turnover cytochrome c re-reduction and
cytochrome b reduction kinetics using chromatophore membranes of
R. capsulatus (Fig. 3). In the absence of any inhibitor, light activation of
the reaction center leads to the oxidation of cytochromes c that are
subsequently re-reduced via the Rieske ISP upon oxidation of QH2 at
the Qo site. The bifurcated electron transfer that occurs at the Qo site
results in the reduction of cytochrome b (i.e., heme bH), which is then
oxidized by the reduction of Q (or SQ) at the Qi site (Fig. 3A, top
panel). The presence of stigmatellin blocks the movement of the
Rieske ISP, abolishing cytochromes c re-reduction after light activa-
tion of the reaction centers, exposing the full extent of cytochromes c
oxidation. Similarly, addition of antimycin A abolishes oxidation of the
cytochromes b revealing the full extent of cytochrome b reduction
(Fig. 3A, top panel). Addition of either 1 or 10 μM ascochlorin
inhibited partially or fully the re-reduction of cytochromes c,
respectively, indicating that Qo site electron transfer was abolished
like stigmatellin (Fig. 3A, middle and bottom panels). Consequently,
no cytochrome b reduction could be seen, clearly indicating thatome b reduction kinetics of R. capsulatus. Chromatophore membranes of R. capsulatus
MKCl (A) or 50mMglycine–NaOH buffer (pH 9.5)/100mMKCl/10 μMmyxothiazol (B)
x potentials were poised at 100 mV where the Qpool is half-reduced and -oxidized at pH
Spectral changes were monitored at 550 minus 540 nm and 560 minus 570 nm for the
ht, respectively.
Fig. 4. Ascochlorin inhibits reduction of cytochrome b in puriﬁed bovine cytochrome bc1 complex through either Qo or Qi site. Bovine bc1 complex was diluted to ∼6 μM(A) or (B, C, and D) in 20 mM potassium MOPS (pH 7.2), 100 mM
NaCl, 0.5 mM EDTA, 5% glycerol, and 0.1 g/l dodecyl maltoside and supplemented with 14 μM azoxystrobin (A), 30 μM antimycin A (B), 31 μM ascochlorin (C), or 364 μM ascoch in (D). A preliminary scan (scan 0) showed the complex to be
fully oxidized. DBH2 was added to 25 μM and the sample was scanned repeatedly, at ∼18-s intervals initially, to follow the redox state of the cytochromes. After about 12 min race of dithionite was added to the cuvette to determine the
maximum extent of reduction. The initial oxidized spectrum was subtracted from all, and the resulting difference spectra (inset in A) were decomposed into sums of the differe spectra of cytochromes c1 (red), bH (green), and bL (blue) as
described in Materials and methods to determine the extent of reduction of each. The results are plotted against time.
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Fig. 5. Spectral effects of binding ascochlorin to the reduced bovine bc1 complex. Bovine
bc1 complex was diluted in 20 mM potassium MOPS (pH 7.2), 100 mM NaCl, 0.5 mM
EDTA, 5% glycerol, and 0.1 g/l dodecyl maltoside and reduced with a trace of solid
sodium dithionite in a stoppered cuvette. The spectra were scanned until no further
change was seen, and then inhibitors were added. For traces 1–3, successive additions
of ascochlorin were made to bring the concentration to 8, 16, and 60 μM inhibitor, and
spectra were recorded after stabilization. The initial dithionite reduced spectrum was
subtracted from each to get the total inhibitor-induced change at each concentration.
For traces 4–7, 33 μM antimycin (4 and 5) or myxothiazol (6 and 7) was added, new
spectra were recorded, and then 33 μM ascochlorin was added. The spectral changes
induced by antimycin and myxothiazol are displayed in traces 4 and 6, respectively.
Traces 5 and 7 show the further spectral changes induced by ascochlorin in the
presence of antimycin or myxothiazol, respectively. The concentration of bc1 was 6 μM,
except traces 4 and 5 (5 μM). The spectra have been divided by the concentration (mM)
to allow direct comparison.
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complex. In addition, the extent of cytochromes c oxidation mediated
by ascochlorin was unlike that seen with myxothiazol, but rather very
similar to that seen with stigmatellin. This suggested that ascochlorin
also immobilized the Rieske ISP upon its binding to the Qo site of the
cytochrome bc1 complex.
Next, in order to examine the binding of ascochlorin to the Qi site,
we monitored the Qi site-mediated reduction of cytochrome b (heme
bH) by blocking the Qo site withmyxothiazol (Fig. 3B). For this reverse
kinetics, we poised the ambient potential of chromatophore mem-
branes at 125 mV in the alkaline pH (pH 9.5) where the Qpool is fully
oxidized. The cytochromes c and b kinetics of the cytochrome bc1
complex were then monitored after light activation of the reaction
center (Fig. 3B). When the Qo site was blocked by the addition of
myxothiazol, antimycin A-sensitive reduction of cytochrome b
through the Qi site was observed (Fig. 3B, top panel). Remarkably,
addition of 1 or 10 μM ascochlorin completely inhibited this
cytochrome b reduction like antimycin A, indicating that ascochlorin
can also bind to the Qi site under the condition where the Qo site is
blocked (Fig. 3B, middle and bottom panels). Therefore, the light-
induced single turnover forward and reverse kinetics clearly showed
that ascochlorin can inhibit both the Qo and Qi sites reactions
catalyzed by the cytochrome bc1 complex.
The results presented in Fig. 4 show that ascochlorin also inhibits
at both Q sites in bovine mitochondrial bc1 complex. Puriﬁed complex
was treated with either the Qo site inhibitor azoxystrobin, the Qi site
inhibitor antimycin, or ascochlorin. Spectra were scanned before and
after adding a small excess of DBH2. Because thoroughly mixing in the
DBH2, closing the cuvette chamber, and starting the scan required 15–
20 s, the uninhibited enzyme reactions are essentially complete
before the ﬁrst scan, and the time courses shown representmainly the
slow approach to equilibrium as the quinol reduces cytochrome c1 by
a nonenzymatic mechanism. In the presence of azoxystrobin (Fig. 4A)
the Qo site is blocked. Cytochrome bH is reduced rapidly before the
ﬁrst scan, while cytochrome c1 is reduced more slowly by a
nonenzymatic mechanism. As this latter reaction raises the potential
of the DBH2/DB couple, cytochrome b is partially reoxidized. In the
presence of antimycin A (Fig. 4B), both cytochrome c1 and b are
rapidly reduced by the bifurcated reaction at Qo. Due to the oxidant-
induced reduction cytochrome bH is reduced to about 80% level and
even cytochrome bL is reduced nearly 20%. As cytochrome c1 and the
high potential chain are further reduced nonenzymatically, the
bifurcated reaction reverses and cytochrome b is reoxidized to a
level of about 10% reduction within a few minutes. With ascochlorin
present, the extent of the rapid reactions is much smaller, with
cytochrome c1 reduced about 20% and cytochrome bH reduced about
10% by the time of the ﬁrst spectrum. This is consistent with
ascochlorin blocking both Qo and Qi sites in most of the complexes,
allowing us to do the double-kill experiment of Duel and Thorn [49]
with a single inhibitor. It might be expected that at subsaturating
concentration ascochlorin would bind preferentially to one site or the
other, giving characteristics similar to either the azoxystrobin-
inhibited or antimycin-inhibited complexes of Fig. 4A and B. This
was not the case: at lower concentrations the extent of the fast
reactions was greater, but as in Fig. 4C the extent of cytochrome c1
reduction was greater than that of cytochrome bH (Fig. S1). This is
characteristic of complexes with both sites active, as the only
enzymatic path for cytochrome c1 reduction is the bifurcated reaction,
and the failure of reduced cytochrome b to accumulate to the same
level implies it is reoxidized by the reaction at Qi. Increasing the
concentration of ascochlorin from 31 to 360 μM further decreased the
extent of the fast reactions by about a factor of two compared to Fig.
4C, as also shown in Fig. S1.
Surprisingly, when ascochlorin and antimycin are both present
(not shown), there is rapid reduction about half of cytochrome bH and
c1, even with 240 μM ascochlorin. This peculiar observation may berelated to the proposal of Covian et al. [50] that binding antimycin at
both Qi sites allows only one Qo site to be in an active conformation.
3.3. Spectral effects on the b hemes
Several inhibitors have been shown to induce changes in the
spectra of the reduced b cytochromes, usually consisting mainly in a
shift of the spectrum toward red or blue wavelengths [51,52]. The
change induced by ascochlorin resembles not so much a red-shift as a
sharpening up of the alpha peak, with troughs on either side of a peak
in the middle. In the absence of other inhibitors, the peak is about
563.5 nm (Fig 5, trace 1–3), and the trough on the long-wavelength
side is more prominent. To distinguish effects at the Qi and Qo site,
ascochlorin was added after saturation of one site or the other with
the tight-binding site-speciﬁc inhibitors antimycin and myxothiazol.
It has been shown in the case of a number of inhibitors that the
spectral effects at Qo and Qi sites are additive [52]. Figure 5 shows the
effects of antimycin (trace 4) and myxothiazol (trace 6) as well as the
further effects induced by adding ascochlorin in the presence of
antimycin (trace 5) or myxothiazol (trace 7). Traces 5 and 7 indeed
appear slightly different, with the peak to longer wavelengths in the
presence of antimycin (when it would be more likely to be interacting
with bL at the Qo site), and slightly shorter wavelength in the presence
of myxothiazol (when it would be interacting with bH at the Qi site).
Fig. 6. Ascochlorin binds to the bc1 complex in the ionized form. Bovine bc1 complex
was diluted to 5.8 μM in 20mM potassiumMOPS (pH 7.2), 100mMNaCl, 0.5 mM EDTA,
and 0.1 g/l dodecyl maltoside in a volume of 0.5 ml. A spectrum was recorded (lower
panel) before (0) and after each of 3 additions: 1 μl of 2 mM (1), 1 μl of 2 mM (2), and
1 μl of 11 mM (3) ascochlorin, bringing the concentration to 4 μM (1), 8 μM (2), and
30 μM (3). Upper panel: the difference spectra resulting from each of the three
additions (corrected for dilution). The similarity of the change on each addition
indicates that bound ascochlorin, like that in neutral aqueous buffer, has spectral
characteristics of the ionized form.
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further investigation.
3.4. Ascochlorin binds in the ionized form
The spectrum of ascochlorin itself is sensitive to pH. Neutral
ascochlorin inmethanol has an absorbance peak at 295. On addition of
NaOH this peak goes away and a signiﬁcantly more intense oneTable 6
Key reﬁnement statistics for the complex III structure with ascochlorin bound at Qo and
Qi sites.
PDB accession code 3H1L
Space group P212121
Cell parameters 174.1×182.4×241.6, 90° 90° 90°
No. atoms reﬁned 32,657
No. reﬂections 125,125 (16,015)
Resolution range 30–3.21
(last shell) 3.37–3.21
Completeness 99.1% (91.3%)
Cryst. R value 0.267 (0.396)
Free R value 0.295 (0.404)
B values
From Wilson plot 86.7 Å2
Mean atomic B value 106.4 Å2
RMS deviations from ideality
Bond lengths 0.009 Å
Bond angles 1.4°
Dihedral angles 21.6°
Improper angles 0.95°appears at 350 (Fig. S2). This is presumably due to ionization of one or
both of the phenolic OH groups, as it is reversible by adding a slight
excess of HCl. Since these peaks are in the spectral window between
absorbance of protein at 280 nm and the Soret peaks at 315 nm, we
can tell whether bound ascochlorin has the spectral characteristics of
the neutral or ionized form.
When the neutral form is added to aqueous buffer (20 mM
potassium MOPS, pH 7.2, 100 mM NaCl, 0.5 mM EDTA, and 0.1 g/
l dodecyl maltoside) at micromolar concentrations, the peak is at 346
(the anionic species, not shown). The peak position is similar
(350 nm) when added in substoichiometric amounts to the bovine
bc1 complex at 6 μM (Fig. 6), and does not change signiﬁcantly as
excess ascochlorin is added. Although the spectra are noisy in the
vicinity of the protein peak at 280 nm, it is clear that the inhibitor is
not absorbing greatly at 295 nm. This indicates that ascochlorin binds
in the ionized form. Alkyl hydroxybenzothiazoles also bind in the
ionized form [53].
3.5. Crystallographic studies
To conﬁrm the dual sites of action and begin to elucidate the
binding mode at each site, crystallographic studies of ascochlorin
binding to vertebrate cytochrome bc1 complex were carried out. The
structure of chicken cytochrome bc1 complex soaked with ascochlorin
was solved at 3.21 Å (Table 6). Ascochlorin could be located at two
sites in the structure of chicken cytochrome bc1 complex soaked with
the inhibitor, corresponding to the Qi and Qo sites as known from the
binding of other inhibitors. Figure 7 shows the position of ascochlorin
at these sites in the context of the 3-subunit “catalytic core” of
cytochrome b, cytochrome c1, and the Rieske iron–sulfur protein.
Figure 8 shows close-ups of the electron density locating the inhibitor,
and the derived models at the Qi (Fig. 8A and B) and Qo (Fig. 8C) sites.Fig. 7. Location of the ascochlorin binding sites within the cytochrome bc1 complex. The
three subunits (cytochrome b, cytochrome c1, and ISP) of a “functional monomer” are
shown. The ascochlorin molecules are the yellow ball-and-stick models indicated by
“Qo” and “Qi” in cytochrome b. The blue and yellow ball-and-stick models are (from top
to bottom) heme c1, and heme bL and bH of cytochrome b. The Rieske iron–sulfur
protein is in the cytochrome b position, with its cluster (green and yellow spheres)
adjacent to ascochlorin at the Qo site.
Fig. 8. Electron density at the Qo and Qi site of ascochlorin-treated cytochrome bc1
complex provides evidence for the mode of binding at each site. (A and B) Two views of
Qi site. His202, Ser206 and Asp229 are potential ligands. (C) Qo site. His161 of the
Rieske iron–sulfur protein, which is in the proximal or “cytochrome b” position, ligates
substituents on the aromatic ring of the inhibitor. Glu272 of cytochrome b shows
density for two alternate conformations; the major one (modeled here) forms an H-
bond with the other side of the aromatic ring. Electron density is a 2Fo-Fc map
contoured at 0.3 e−/A3.
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Cl atom, as seen for example in the data of Table 2 (compare
ascochlorin and LL-Z1272ɛ). While the Cl atom could be important for
electronic effects on other aromatic ring substituents, the structure
seems to suggest (see below) that Cl is actually involved in the
interactionwith the protein at both sites. If so it is most likely a type of
interactionknownas the “halide bond” [54]. This interaction involves a
polar carbon–halogen bond interacting with electronegative O or N
atom. The distance to the latter is somewhat less than the sum of the
Van der Waals radii, and the angle C-X-O or C-X-N is approximately
linear [54]. Within the limitations of a structure of this resolution, the
interactions observed here seem to conformwith this description. The
data of Tables 1and 2 additionally show that the 4-OH of ascochlorin is
important for inhibition.
At the Qi site, the aromatic ring is sandwiched between the bent-
back propionate of heme bH and the ring of Phe221 of cytochrome b
(Fig. 8B), apparently H-bonding with His202 and Asp229 (Fig. 8A).
The orientation of ascochlorin aromatic ring is not completely
unambiguous in this structure. In particular, it is possible that the
ring could be ﬂipped 180° compared to the model shown, or that both
orientations are present. Qualitatively though the best ﬁt to the
density seems to be obtained with the chloride (Cl) atom making a
halide bond [54] with His202 and the OH group para to the Cl
donating an H-bond to Asp229. In either case, this position
corresponds closely to the position of the aromatic ring of ubiquinone
seen in crystals of the chicken [55], yeast [56], and bovine [32]
cytochrome bc1 complex and the aromatic salicylamide moiety of
antimycin [57]. Interestingly, while the aromatic head groups of
antimycin and ascochlorin lie in the same plane and largely overlap,
the alkyl tails (including the dilactone ring of antimycin) leave the
head groups at about 90° angles from each other, with antimycin
following the groove between helices A and D (and making Van der
Waals contact with heme bH through the crack between them) while
the tail of ascochlorin is located more between the helices A and E.
Electron density was also present for ascochlorin binding at the Qo
site. In the presence of ascochlorin the Rieske ISP is found in the
cytochrome b position, where it forms part of the Qo site, as with
stigmatellin. In structures obtained using this crystal form in the
absence of inhibitor or in the presence of “proximal” Qo inhibitors
such as myxothiazol or azoxystrobin, the Rieske ISP is found in the
cytochrome c1 position. Comparing this structure with structures
containing stigmatellin, the aromatic ring of ascochlorin is in a
position overlapped by the aromatic head of stigmatellin (PDB IDs
2PPJ, 3H1J). An H-bond is clearly present between ascochlorin and
His161 of the Rieske ISP, which is one of the 2Fe2S cluster ligands. The
other side of ascochlorin ring is in H-bonding distance of a density
attributed to Glu272. Although again, the bonding partners cannot be
unambiguously identiﬁed, the model presented here ﬁts well, with
the Cl of the inhibitor bonding Glu272, and its C=O or OH group (or
both) binding the His161 N atom of the Rieske ISP. The tail of
ascochlorin also overlaps the position occupied by stigmatellin, with
the cyclohexyl group at the end of the tail occupying the same space as
the two methoxy groups in the tail of stigmatellin. This also
corresponds to the position of the second thiazol in the tail of
myxothiazol. Clearly there is room for an expansion of the tail at this
point. After this point, the tails of stigmatellin and myxothiazol
diverge into the bulk lipid phase, but that of ascochlorin does not
extend beyond this point.
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structures, and probably there is a mixture of conformations. In the
ﬁrst monomer (chain C), there is density that could be the carboxylate
of Glu272 H-bonding the inhibitor, but it is not continuous with the
backbone of Glu272, and so it has been modeled as a water molecule
and Glu272 has been rotated away to the rotamer 31 position. In the
second monomer (chain P) it has been modeled as in stigmatellin,
with Glu272 in rotamer 4 conﬁguration, making H-bonds with the
inhibitor and the N of Glu272.
4. Discussion
In this work, we have shown that ascochlorin inhibits the
cytochrome bc1 complex by binding at both the Qi and Qo sites of
the enzyme. Ascochlorin may be a general quinone analog, as it also
inhibits the ubiquinone sites in the ubiquinol oxidases (E. coli bo and
trypanasome alternative oxidase) [25]. In this respect, it resembles
the NQNO-type inhibitors that inhibit the complex II, quinol:fumarate
reductase [58], formate dehydrogenase, bo-type ubiquinol oxidase
[59], glycerol phosphate dehydrogenase [60], cytochrome b6f [61], and
both the Qo and Qi sites of the cytochrome bc1 complex [32]. Further,
while funiculosin is generally considered to bind at the Qi site, there
have been several reports indicating its interaction with the Qo site
[62-64]. Tsai et al. [62] reported that it also affected the EPR lineshape
and midpoint potential of the Rieske ISP, which is structurally distant
from the Qi site and adjacent to the Qo site. Howell and Robertson [63]
reported spectral effects of the Qi site inhibitor funiculosin on heme bL,
which is near the Qo site. Degli Esposti and co-workers [64] suggested
that replacement of Ala by Met at a position corresponding to 126 in
yeast mitochondrial cytochrome b (close to the Qo site) was partially
responsible for resistance to funiculosin in ﬁsh. It therefore appears
that a group of cytochrome bc1 complex inhibitors affects both of the
active sites of this enzyme. Among them ascochlorin is unusual in that
its binding at both of these active sites involves a halide bondwith the
Cl atom. This bond occurs apparently with a histidine N at the Qi site,
and with a carboxylate or water at the Qo site, whereas most of the
other inhibitors involve an (CH—N), or (CH—O) H-bond, respectively.
While the structural details of these bindings are not particularly clear
in the current low-resolution structure, this unique information may
lead to new approaches for designing inhibitory analogs as drugs and
pesticides. Inhibitors that might bind to both of the active sites of the
cytochrome bc1 complexmight be invaluable, as occurrence of natural
resistance to these kinds of dual-action inhibitors would be much
lower than those acting only at one of the two sites. Therefore, itwill be
important to obtain higher resolution data to better deﬁne the binding
properties of ascochlorin, and in particular, to localize with higher
precision the exact location of the Cl atom possibly by using its
anomalous signal and greater electron density. At the Qo site,
ascochlorin seems to act like stigmatellin that ﬁxes the Rieske ISP in
the cytochrome b position, based on the EPR (Fig. 2), the single light-
induced forward kinetics (Fig. 3A), and the 3D-structural (Fig. 8C)
data. Finally, it is worthy to note that the head group of ascochlorin is
shaped more like the ubiquinone head-group as compared with the
other inhibitors so far located at the Qo site, and thus its precise
localization might provide a better model for visualizing ubiquinone
binding at this active site of the cytochrome bc1 complex.
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